Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the efficacy and safety of IMC-002 and IMM0306S in the treatment of active SLE.

Participants needed: 218
Trial details
Phase: Phase 1, Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.Updated: Jun 29, 2026Locations: 1
Eligibility criteria

Has had a diagnosis of SLE for at least 12 weeks prior to the screening Visit. [+4]

Active or unstable neuropsychiatric SLE or lupus nephritis [+5]

Read more
Status: Recruiting

A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.

This is a Phase Ib/IIa clinical study of IMC-003 treatment in pulmonary arterial hypertension (PAH) patients receiving background therapy

Participants needed: 120
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.Updated: May 18, 2026Locations: 32
Eligibility criteria

Age screening between 18 and 75 years (inclusive), regardless of gender. [+9]

Diagnosed with pulmonary hypertension of WHO Group 2, 3, 4, or 5. [+17]

Read more
Status: Not yet recruiting

A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients

The purpose of this study is to evaluate the efficacy and safety of IMC-002 in the treatment of NMOSD.

Participants needed: 116
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.Updated: Aug 16, 2024
Eligibility criteria

Age 18 to 70 years, inclusive, at the time of informed consent [+4]

Have received rituximab or other anti-CD20 drugs treatment within 6 months [+3]

Read more